Oragenics Inc. · AMEX:OGEN
Oragenics — Investor Presentation (October 2013)
20 slides from Oragenics's investor presentation, Oct 18, 2013
Slide 1: Engineering New Antibiotics and Probiotics Through Synthetic Biology
Exhibit 99.1 Engineering New Antibiotics and Probiotics Through Synthetic Biology Investor Presentation October 2013
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements made in this presentation include forward-looking actions that Oragenics, Inc. (“Oragenics,” or the “Company”) anticipates based on certain assumptions. These statements are indicated by words such as “expect,” “anticipate,” “should” and similar words indicat
Slide 3: Introduction
Introduction 1 OragenicsInc. (NYSEMKT: OGEN,market cap $83M ) is focused on leveragin g its expertise in lantibiotics and probiotics with Intrexon’s leading synthetic biology platform via two exclusive channel collaborations (ECCs) to develop novel biotherapeutics, including: 1. Lantibiotics: a nove
Slide 4: A Platform for Rapidly Engineering Bacterial Systems
A Platform for Rapidly Engineering Bacterial Systems Inventoried DNA Modules Genetically Modified Bacterial Cell 1. Lantibiotic Production 2. Next Generation Probiotics 3
Slide 5: Serious Need for New Antibiotics
Serious Need for New Antibiotics “We Will Soon Be in a Post-Antibiotic Era” The Sep. 2013 CDC report making headlines highlighted the serious threats of antibiotic- resistant infections and the need for new antibiotics: Over 2 million infections and 23,000 deaths each year in the U.S. are caused by
Slide 6: Trends Support CDC Concerns
Trends Support CDC Concerns Resistance Increases While Approvals Decrease Resistant Bacterial Strains Spread Rapidly Total Approved Bacterials US- 5
Slide 7: Lantibiotics
Lantibiotics A Promising Solution to the Growing Health Crisis of Antibacterial Resistance Lantibiotics are a novel class of peptide antibacterial compounds: • Naturally-produced by a variety of Gram-positive bacterial strains to attack competing bacterial strains • There are more than 50 known lant
Slide 8: Lead Lantibiotic Compound MU1140
Lead Lantibiotic Compound MU1140 Initial focus is on MU1140, a lantibiotic shown to be effective against: • Methicillin-resistant Staphylococcus aureus (MRSA) • Vancomycin-resistant Enterococcus (VRE) • Clostridium difficile (C. diff) • Resistant Tuberculosis • Other Gram positive bacteria Prelimina
Slide 9: Plan for MU1140
Plan for MU1140 First of 50+ Known Lantibiotics Intrexon collaboration has already produced a significant increase in fermentation titer and is developing a promising new purification process Matrix of early experiments planned to screen MU1140 (and several analogs/homologs) for determining primary
Slide 10: Synthetic Biology Enables Lantibiotics
Synthetic Biology Enables Lantibiotics Synthetic biology is the application of engineering principles to the design of living organisms and their constituent parts (DNA, proteins, and cells) We are collaborating with Intrexon, a leading synthetic biology company, for the development and commercializ
Slide 11: With Intrexon Collaboration
With Intrexon Collaboration Lantibiotics –For Resistant Bacterial Infections Bacteria Cell Lantibiotics (50+ known) Extract genes …insert …and produce MU1140 responsible for genes into and pipeline lantibiotics lantibiotic modified via fermentation at production bacteria to commercial scale. from na
Slide 12: Rising Market Demand for Novel Antibiotic Platforms
Rising Market Demand for Novel Antibiotic Platforms Significant valuations for “Single Antibiotic Product” companies – Oragenics has potential to generate a pipeline of lantibiotics Commercial Cubist Market cap: $ Cubist Acquisitions approx. $4.2B (7/31/13) Approved/Late Stage Deal size: approx. $81
Slide 13: Next Generation Probiotics
Next Generation Probiotics Potential to Revolutionize Probiotics for Oral Diseases We are also developing, in collaboration with Intrexon, novel probiotics focusing on the treatment of patients with oral cavity, throat, sinus, and esophageal diseases Initial indications: • Behçet’s diseasea- chronic
Slide 14: Lead Probiotic Programs
Lead Probiotic Programs Behçet’s Disease and Aphthous Stomatitis Behçet’s disease - a chronic relapsing multi-systemic inflammatory disorder characterized by four major symptoms (oral aphthous ulcers, genital ulcers, skin lesions, and ocular lesions) Patients suffering from Behçet’s disease are ofte
Slide 15: Oragenics/Intrexon Solution: GM Probiotics For Oral Health
Oragenics/Intrexon Solution GM Probiotics For Oral Health Bacteria Cell …insert genes …and deliver new Choose the responsible for therapeutic bacteria appropriate production of into the oral cavity to bacterial strain therapeutics produce therapeutic to engineer… agent(s)… benefits and supplement th
Slide 16: ProBiora3 - OTC Product
ProBiora3® - OTC Product First and Only Patented Probiotic Technology for Oral Care Blend of 3 naturally-occurring, non-pathogenic bacteria – S.oralis, S.uberis, and S.rattus – is available without prescription and taken daily “Good” probiotic bacteria in ProBiora3 ® compete for binding sites and nu
Slide 17: Significant Accomplishments in Last Year
Significant Accomplishments in Last Year Novel Antibiotics (Lantibiotics) Significantly increased yield of MU1140making commercialization a realistic goal Identified two new potentially viable purification methods for commercially producing MU1140 Progress toward a genetically modified bacteria capa
Slide 18: Upcoming Milestones
Upcoming Milestones Novel Antibiotics (Lantibiotics) Production of new lantibiotic analogs using genetically - modified bacteria – 1H ‘14 Animal study results on MU1140/analog – 2H ‘13 Announcement of results from pre-IND meeting with FDA- Mid ’14 Next Generation Probiotics (Preliminary Timelines) G
Slide 19: Experienced Management Team
Experienced Management Team John N. Bonfiglio, Ph.D., President, CEO & Director 30 years of management and pharmaceutical experience Prior CEO Argos Therapeutics, CEO Immune Response, CEO Peregrine Pharmaceuticals, COO Cypress Bio Senior Management positions at Allergan Pharmaceuticals and Baxter He
Slide 20: Corporate Summary
Corporate Summary NYSEMKT: OGEN Share price (as of 10/9/13) : $3.00 Market cap (as of 10/9/13) : $83M* Sharesoutstanding (as of 6/30/13) : 27.5M* Cash (as of 6/30/13) : $6.4M* Debt (as of 6/30/13) : $142,000* Warrants and Options (as of 6/30/13) : 2.7M warrants and 670,000 options outstanding *exclu